GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celularity Inc (NAS:CELU) » Definitions » Profitability Rank

Celularity (Celularity) Profitability Rank : 1 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Celularity Profitability Rank?

Celularity has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Celularity's Operating Margin % for the quarter that ended in Sep. 2023 was -436.93%. As of today, Celularity's Piotroski F-Score is 2.


Competitive Comparison of Celularity's Profitability Rank

For the Biotechnology subindustry, Celularity's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celularity's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celularity's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Celularity's Profitability Rank falls into.



Celularity Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Celularity has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Celularity's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=-16.542 / 3.786
=-436.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Celularity has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Celularity Profitability Rank Related Terms

Thank you for viewing the detailed overview of Celularity's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Celularity (Celularity) Business Description

Traded in Other Exchanges
N/A
Address
170 Park Avenue, Florham Park, NJ, USA, 07932
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.
Executives
Kok Thay Lim director 22ND FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Robert J Hariri director, officer: Chief Executive Officer 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Ling Geoffrey M.d. director C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
Berhad Genting 10 percent owner 24TH FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Adrian Kilcoyne officer: See Remarks 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
John Sculley director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kyle Fletcher officer: General Counsel CELULARITY INC., 170 PARK AVE., FLORHAM PARK NJ 07932
Peter Diamandis director 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292
Dean C Kehler director C/O TRIMARAN CAPITAL PARTNERS, 622 THIRD AVENUE, 35TH FLOOR, NEW YORK NY 10017
Robin L Smith director C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Marc Mazur director 31 WEST 52ND ST. 17TH FLOOR, NEW YORK NY 10019
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Bradley Glover director, officer: Chief Technology Officer C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Stephen Brigido officer: Pres, Functional Regeneration C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Anne Jones director, officer: Chief Business Officer C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932

Celularity (Celularity) Headlines

From GuruFocus

Is Celularity Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 12-01-2022

Celularity Appoints Paul Graves as Chief Communications Officer

By Stock market mentor Stock market mentor 01-04-2023

Is Celularity Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 11-30-2022